신생아중환자의 약동학적 다양성에 영향을 미치는 요인

키워드

참고문헌 (77)

1. Friis-Hansen B, "Water distribution in the foetus and newborn infant", Acta Peadiatr Scand Suppl, 305, pp.7~11 (1983)
2. Pai VB, "Clinical pharmacokinetics", pp.29~44 (2011), Am Soc Healthsyst Pharm
3. Vanpée M, "Renal function in very low birth weight infants : normal maturity reached during early childhood", J Pediatr, 121, pp.784~788 (1992)
4. Kearns GL., "Pharmacogenetics and development: are infants and children at increased risk for adverse outcomes?", Curr Opin Pediatr, 7, pp.220~233 (1995)
5. Taketomo CK, "Pediatric & Neonatal Dosage Handbook" (2015), Lexi-Comp
6. Morselli PL, "Clinical pharmacokinetics in newborns and infants", Clin Pharmacokinet, 5, pp.485~527 (1980)
7. Besunder JB, "Principles of drug disposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface", Clin Pharmacokinet, 14, pp.189~216 (1988)
8. Friedman CA, "Gentamicin disposition in asphyxiated newborns : relationship to mean arterial pressure and urine output", Pediatr Pharmacol(New York), 2, pp.189~197 (1982)
9. Touw DJ, "Clinical pharmacokinetics of phenobarbital in neonates", Eur J Pharm Sci, 12(2), pp.111~116 (2000)
10. Donn SM, "Safety of a Higher Loading Dose of Phenobarbital in the Term Newborn", Pediatrics, 75(6), pp.1061~1064 (1985)
11. Heimann G, "Pharmacokinetics of Phenobarbital in Childhood", Eur J Clin Pharmacol, 12(4), pp.305~310 (1977)
12. Yukawa M, "Population pharmacokinetics of phenobarbital by mixed effect modelling using routine clinical pharmacokinetic data in Japanese neonates and infants : an update", J Clin Pharm Ther, 36(6), pp.704~710 (2011)
13. Marsot A, "Pharmacokinetics and absolute bioavailability of phenobarbital in neonates and young infants, a population pharmacokinetic modelling approach", Fundam Clin Pharmacol, 28(4), pp.465~471 (2014)
14. Lee SM, "Effects of cytochrome P450(CYP)2C19 polymorphisms on pharmacokinetics of phenobarbital in neonates and infants with seizures", Arch Dis Child, 97(6), pp.569~572 (2012)
15. van den Broek MP, "Pharmacokinetics and clinical efficacy of phenobarbital in asphyxiated newborns treated with hypothermia : a thermopharmacological approach", Clin Pharmacokinet, 51(10), pp.671~679 (2012)
16. Shellhaas RA, "Population pharmacokinetics of phenobarbital in infants with neonatal encephalopathy treated with therapeutic hypothermia", Pediatr Crit Care Med, 14(2), pp.194~202 (2013)
17. Filippi L, "Phenobarbital for neonatal seizures in hypoxic ischemic encephalopathy : a pharmacokinetic study during whole body hypothermia", Epilepsia, 52(4), pp.794~801 (2011)
18. Pitlick W, "Phenobarbital pharmaockinetics in neonates", Clin P harmacol Ther, 23(3), pp.346~350 (1978)
19. Grasela TH Jr, "Neonatal population pharmacokinetics of phenobarbital derived from routine clinical data", Dev Pharmacol Ther, 8(6), pp.374~383 (1985)
20. Kim SE, "Population pharmacokinetics of theophylline in premature Korean infants", Ther Drug Monit, 35(3), pp.338~344 (2013)
21. Fukuda T, "Population pharmacokinetics of theophylline in very premature Japanese infants with apnoea", J Clin Pharm Ther, 30(6), pp.591~596 (2005)
22. Jones RA, "Dosage schedule for intravenous aminophylline in apnoea of prematurity, based on pharmacokinetic studies", Arch Dis Child, 54(3), pp.190~193 (1979)
23. Dothey CI, "Maturational changes of theophylline pharmacokinetics in preterm infants", Clin Pharmacol Ther, 45(5), pp.461~468 (1989)
24. Aranda JV, "Pharmacokinetics of diuretics and methylxanthines in the neonate", Eur J Clin Pharmacol, 18(1), pp.55~63 (1980)
25. Brazier JL, "Plasma xanthine levels in low birth weight infants treated or not treated with theophylline", Arch Dis Child, 54(3), pp.194~199 (1979)
26. Islam SI, "Pharmacokinetics of theophylline in preterm neonates during the first month of life", Saudi Med J, 25(4), pp.459~465 (2004)
27. Moore ES, "The population pharmacokinetics of theophylline in neonates and young infants", J Pharmacokinet Biopharm, 17(1), pp.47~66 (1989)
28. Young TE, "Neofax" (2011), Thomson Reuters
29. Pacifici GM, "Clinical pharmacokinetics of aminoglycosides in neonates : a review", Eur J Clin Pharmacol, 65, pp.419~427 (2009)
30. Olavarría F, "Influence of gestational age and postnatal kidney maturation on the kinetics of gentamicin", Rev Chil Pediatr, 61(2), pp.86~90 (1990)
31. An SH, "Outcomes of a new dosage regimen of amikacin based on pharmacokinetic parameters of Korean neonates", Am J Health-Syst Pharm, 71, pp.122~127 (2014)
32. Treluyer JM, "Nonparametric population pharmacokinetic analysis of amikacin in neonates, infants and children", Antimicrob Agents Chemother, 46, pp.1381~1387 (2002)
33. Allegaert K, "Limited predictability of amikacin clearance in extreme premature neonates at birth", Br J Clin Pharmacol, 61, pp.39~48 (2006)
34. Peterson PO, "Amikacin dosing in neonates : evaluation of a dosing chart based on population pharmacokinetic data", Dev Pharmacol Ther, 16, pp.203~211 (1991)
35. Nielsen EI, "Developmental pharmacokinetics of gentamicin in preterm and term neonates : population modeling of a prospective study", Clin Pharmacokinet, 48(4), pp.253~263 (2009)
36. McDougal A, "Vancomycin pharmacokinetics and dosing in premature neonates", Ther Drug Monit, 17(4), pp.319~326 (1995)
37. Lulic-Botica M, "Impact of small-for-gestational age(SGA)status on gentamicin pharmacokinetics in neonates", J Clin Pharmacol, 54(1), pp.39~45 (2014)
38. Radde IC., "Pediatric pharmacology and Therapeutics", pp.87~ (1993), Mosby- Tear Book
39. deHoog M, "Vancomycin : pharmacokinetics and administration regimens in neonates", Clin Pharmacokinet, 43(7), pp.417~440 (2004)
40. James A, "Vancomycin pharmacokinetics and dose recommendations for preterm infants", Antimicrob Agents Chemother, 31(1), pp.52~54 (1987)
41. Jarrett RV, "Individualized pharmacokinetic profiles to compute vancomycin dosage and dosing interval in preterm infants", Pediatr Infect Dis J, 12(2), pp.156~157 (1993)
42. Rodvold KA, "Bayesian forecasting of serum vancomycin concentrations in neonates and infants", Ther Drug Monit, 17(3), pp.239~246 (1995)
43. Rhodin MM, "Human renal function maturation : a quantitative description using weight and postmenstrual age", Pediatr Nephrol, 24, pp.67~76 (2009)
44. Kildoo CW, "Vancomycin pharmacokinetics in infants : relationship to postconceptional age and serum creatinine", Dev Pharmacol Ther, 14(2), pp.77~83 (1989)
45. Grimsley C, "Pharmacokinetics and dose requirements of vancomycin in neonates", Arch Dis Child Fetal Neonatal Ed, 81(3), pp.F221~F227 (1999)
46. Capparelli EV, "The influences of renal function and maturation on vancomycin elimination in newborns and infants", J Clin Pharmacol, 41(9), pp.927~934 (2001)
47. Frymoyer A, "Gentamicin pharmacokinetics and dosing in neonates with hypoxic ischemic encephalopathy receiving hypothermia", Pharmacotherapy, 33(7), pp.718~726 (2013)
48. Gilman JT, "Factors influencing theophylline disposition in 179 newborns", Ther Drug Monit, 8(1), pp.4~10 (1986)
49. Gal P, "The influence of asphyxia on phenobarbital dosing requirements in neonates", Dev Pharmacol Ther, 7(3), pp.145~152 (1984)
50. Gal P, "Effect of asphyxia on theophylline clearance in newborns", South Med J, 75(7), pp.836~838 (1982)
51. Friedman CA, "Gentamicin disposition in asphyxiated newborns : relationship to mean arterial blood pressure and urine output", Pediatr Pharmacol(New York), 2(3), pp.189~197 (1982)
52. Zanelli S, "Physiologic and pharmacologic considerations for hypothermia therapy in neonates", J Perinatol, 31(6), pp.377~386 (2011)
53. Van den Broek MPH, "Effects of hypothermia on pharmacokinetics and pharmacodynamics", Clin Pharmacokin, 49, pp.277~294 (2010)
54. Mark LF, "Gentamicin pharmacokinetics in neonates undergoing therapeutic hypothermia", Ther Drug Monit, 35, pp.217~222 (2013)
55. Ting JY, "Pharmacokinetics of gentamicin in newborns with moderate-to-severe hypoxicischemic encephalopathy undergoing therapeutic hypothermia", Ind J Pediatr, 82, pp.119~125 (2015)
56. Frymoyer A, "Decreased Morphine Clearance in Neonates With Hypoxic Ischemic Encephalopathy Receiving Hypothermia", J Clin Pharmacol, 57(1), pp.64~76 (2017)
57. Cies JJ, "Population Pharmacokinetics and Pharmacodynamic Target Attainment of Ampicillin in Neonates with Hypoxemic-Ischemic Encephalopathy in the Setting of Controlled Hypothermia", Pharmacotherapy, 37(4), pp.456~463 (2017)
58. Bartlett RH, "Extracorporeal membrane oxygenation (ECMO) in neonatal respiratory failure. 100 cases", Ann Surg, 204(3), pp.236~245 (1986)
59. Buck ML, "Pharmacokinetic changes during extracorporeal membrane oxygenation; Implications for drug therapy of neonates", Clin Pharmacokinet, 42(5), pp.403~417 (2003)
60. Marasco SF, "Review of ECMO (extra corporeal membrane oxygenation) support in critically ill adult patients", Heart Lung Circ, 17(Suppl 4), pp.S41~S47 (2008)
61. Lawson G, "Drug disposition during extracorporeal membrane oxygenation(ECMO)", Paediatric Perinatal Drug Ther, 4, pp.109~120 (2001)
62. Cohen P, "Gentamicin pharmacokinetics in neonates undergoing extracorporeal membrane oxygenation", Pediatr Infect Dis J, 9(8), pp.562~566 (1990)
63. Dodge WF, "Population pharmacokinetic models : effect of explicit versus assumed constant serum concentration assay error patterns upon parameter values of gentamicin in infants on and off extracorporeal membrane oxygenation", Ther Drug Monit, 16(6), pp.552~559 (1994)
64. Amaker RD, "Pharmacokinetics of vancomycin in critically ill infants undergoing extracorporeal membrane oxygenation", Antimicrob Agents Chemother, 40, pp.1139~1142 (1996)
65. Buck ML, "Vancomycin pharmacokinetics in neonates receiving extracorporeal membrane oxygenation", Pharmacotherapy, 18(5), pp.1082~1086 (1998)
66. Geiduschek JM, "Morphine pharmacokinetics during continuous infusion of morphine sulfate for infants receiving extracorporeal membrane oxygenation", Crit Care Med, 25, pp.360~364 (1997)
67. Peters JW, "Morphine pharmacokinetics during venoarterial extracorporeal membrane oxygenation in neonates", Intensive Care Med, 31, pp.257~263 (2005)
68. Ahsman MJ, "Population pharmacokinetics of midazolam and its metabolites during venoarterial extracorporeal membrane oxygenation in neonates", Clin Pharmacokinet, 49, pp.407~419 (2010)
69. Ahsman MJ, "Pharmacokinetics of cefotaxime and desacetylcefotaxime in infants during extracorporeal membrane oxygenation", Antimicrob Agents Chemother, 54, pp.1734~1741 (2010)
70. Wildschut ED, "Pharmacotherapy in neonatal and pediatric extracorporeal membrane oxygenation(ECMO)", Curr Drug Metab, 13, pp.767~777 (2012)
71. Williams BS, "Gentamicin pharmacokinetics in neonates with patent ductus arteriosus", Crit Care Med, 25, pp.273~275 (1997)
72. Watterberg KL, "Effect of patent ductus arteriosus on gentamicin pharmacokinetics in very low birth weight (less than 1,500 g) babies", Dev Pharmacol Ther, 10(2), pp.107~117 (1987)
73. Gal P, "Gentamicin in neonates : the need for loading dose", Am J Perinatol, 7, pp.254~257 (1990)
74. Touw DJ, "Gentamicin pharmacokinetics in preterm infants with a patent and a closed ductus arteriosus", Pharm World Sci, 23(5), pp.200~204 (2001)
75. Zarfin Y, "Possible indomethacin-aminoglycoside interaction in preterm infants", J Pediatr, 106(3), pp.511~513 (1985)
76. Allegaert K., "The impact of ibuprofen or indomethacin on renal drug clearance in neonates", J Matern Fetal Neonatal Med, 22(Suppl 3), pp.88~91 (2009)
77. Matic M, "Effect of UGT2B7 -900G>A (-842G>A; rs7438135) on morphine glucuronidation in preterm newborns:results from a pilot cohort", Pharmacogenomics, 15(12), pp.1589~1597 (2014)

관련 논문AI추천